Prognostic Significance of Serum Lactic Acid, Lactate Dehydrogenase, and Albumin Levels in Patients with Metastatic Colorectal Cancer.

Aim. To identify the population of patients with high risk of distant metastasis and the poor prognosis before treatment, so as to provide early intervention and better treatment decision. Method. 69 patients with nonmetastatic colorectal cancer (non-mCRC) and 57 with metastatic CRC (mCRC) were enrolled to evaluate the prognostic value of serum albumin (ALB), serum lactate (SLA), and lactate dehydrogenase (LDH) in patients with metastatic CRC. We then followed up the 57 patients with mCRC. The T test, Chi square test, Kaplan-Meier survival analysis model, and Multivariate Cox proportional hazards regression model were applied to assess the prognostic significance of SLA, LDH, and serum ALB on the patients with mCRC. Results. Compared with the non-mCRC group, the patients with mCRC had an elevated level of blood lactate (P=0.01) and LDH(P<0.01) and a reduced level of ALB (P<0.01). Multivariable analysis showed the elevated LDH combined with elevated SLA (HR=2.922, 95% CI=0.971-8.793, P=0.056), the reduced ALB (HR=0.417, 95% CI=0.230-0.754, P=0.004), and the elevated CA199 (HR=2.072, 95% CI=1.125-3.816, P=0.019) were independent prognostic factors for PFS of patients with mCRC. The elevated LDH (HR=2.204, 95% CI=1.000-4.858, P=0.050), reduced ALB (HR=0.459, 95% CI=0.236-0.892, P=0.022), elevated LDH combined with elevated SLA (HR=3.187, 95% CI=1.0199.970, P=0.046), and the primary site of tumor (HR=0.359, 95% CI=0.174-0.740, P=0.006) were independent prognostic factors for OS of patients with mCRC. Conclusions. Taken together, our results implicate that the elevated LDH combined with elevated SLA and the reduced ALB are prognostic indicators for patients with mCRC.